摘要
Background: Disruption of the DNA damage repair (DDR) gene is related to cancer progression, treatment selection, and is subjected to radiation and targeted therapies with limited success. This paper conducted a comprehensive analysis to explore the distribution of DDR mutations in Chinese pan-cancer patients. @@@ Methods: A total of 10,284 consecutive cases were analyzed in 24 cancer types [non-small cell lung cancer (NSCLC) 29.0%, liver 12.0%, colorectum 10.7%, etc.]. Tumor tissue samples were subjected to next generation sequencing (NGS) using a 381 gene panel incorporating 100 microsatellite loci. The association of deleterious somatic DDR mutation (del-sDDR(mut)) with tumor mutational burden (TMB), microsatellite instability (MSI), programmed cell death-ligand 1 (PD-L1) expression of pan-cancers was evaluated. Genomic and clinical data from public cohorts of immunotherapy were analyzed to demonstrate the association between del-sDDR(mut) and clinical survival. @@@ Results: Del-sDDR(mut) were found in 802 (7.6%) of all cases, and were most common in cancers of the endometrium, prostate, bladder, etc. cancer with a higher TMB also had a higher prevalence of mutations in DDR pathways. The results of the ridge regression analysis showed that 20 DDR genes were significantly associated with TMB [false discovery rate (FDR) <0.01]. A total of 8,899 patients had both TMB and MSIdata in pan-cancers. Seventy-four percent of patients with MSI-high (MSI-H) were accompanied by del-sDDR(mut)/TMB-high (TMB-H). The largest proportion of patients with microsatellite stability (MSS) with DDR mutations were classified as TMB-H. The top 6 tumors (NSCLC, melanoma, esophagus, head and neck, thyroid, and mediastinal) had the highest prevalence of PD-L1 >= 1%, and DDR mutations were significantly associated with a higher percent of PD-L1 positive (P<0.05). Furthermore, in the immune cohort analysis of NSCLC, patients with del-sDDR(mut) significantly improved median progression-free survival (mPFS) and median overall survival (mOS) compared to wild-type DDR patients (P=0.002 and P=0.043), with higher TMB observed (P<0.001). @@@ Conclusions: This study explored the association of DDR mutations with TMB, MSI-H, and PD-L1 expression, and revealed that patients with DDR mutations have a significantly improve prognosis than wild-type patients on immunotherapy.
学科与关键词
- DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patientsGu, Weiguang*; Zhuang, Wenya; Zhuang, Mengxia; He, Minhong; Li, ZhihuaDiagnostic Pathology, 2023, 18(1): 119.
- DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort studyXiao, Zhiwei; Sun, Lingling; Zheng, Yating; Chen, Hanrui; Zheng, Xinting; Luo, Jiamin; Gu, Chuying; Lin, Ruiting; Huang, Mengli; Bai, Yuezong; Chen, Zhe-Sheng; Kinslow, Connor J.; Loh, Jerold; Lin, Lizhu*Translational Lung Cancer Research, 2022, 11(12): 2539-U159.
- A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancerDing, Ke; He, Youhua; Wei, Jinfen; Fu, Shuying; Wang, Jiajian; Chen, Zixi; Zhang, Haibo; Qu, Yimo; Liang, Keying; Gong, Xiaocheng; Qiu, Li; Chen, Dong; Xiao, Botao*; Du, Hongli*Frontiers in Immunology, 2022, 13: 943090.被引 3
